Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Hydroxyurea Shows Some Benefits in Milder Sickle Cell Disease

2.

Prostate cancer therapies: AI-based image analysis detects early organ damage

3.

ACS Guidelines Expand Lung Cancer Screening Eligibility -- Is That a Good Thing?

4.

Colon cancer and exercise: Can physical activity reprogram genes?

5.

Launch of the hereditary cancer clinic for precision oncology at Kokilaben Hospital.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot